Helmholtz Zentrum Munchen Deutsches Forschungszentrum Fur Gesundheit Und Umwelt

Eberhard Karls Universitat Tubingen Medizinische F Akultat

Deutsche Diabetes-forschungsgesellschaft E.v.—trager Des Deutschen Diabetes-zentrums Dusseldorf

Drk Blutspendedienst Baden-wurttemberg-hessen Ggmbh

Christian Herder

Thomas Meitinger

Jerzy Adamski

Erhard Seifried

Torsten Tonn

Manuel Grez

Martin Hrabe De Angelis

Hans-Ulrich Haring

Christine Meisinger

Annette Peters

Michael Roden

H-Erich Wichmann

Zhongao Yu

Rui Wang-Sattler

Thomas Illig

Wolfgang Rathmann

Hans-Ulrich Häring

Martin HrabÉ De Angelis

The present invention relates to a method of identifying a predisposition for developing type 2 diabetes mellitus in a subject, said method comprising the step of assessing in a sample obtained from said subject the amount of one or more metabolite(s) selected from (a) a first group comprising the metabolites glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2, phosphatidylcholine acyl-alkyl C36:3 and isobaric metabolites having the same molecular mass as glycine, lysoPhosphatidylcholine acyl C18:2, lysoPhosphatidylcholine acyl C17:0, lysoPhosphatidylcholine acyl C18:0, lysoPhosphatidylcholine acyl C18:1, phosphatidylcholine acyl-alkyl C34:2, phosphatidylcholine acyl-alkyl C36:2 or phosphatidylcholine acyl-alkyl C36:3 but different chemical formula; and/or (b) a second group comprising the metabolite acetylcarnitine C2 and an isobaric metabolite having the same molecular weight as acetylcarnitine C2 but different chemical formula; wherein a decrease in the amount of a metabolite selected from said first group or an increase in the amount of a metabolite selected from said second group as compared to the amount of the corresponding metabolite(s) of a control is indicative of a predisposition to develop type 2 diabetes mellitus. Further, the invention relates to a method of identifying a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith or serving as a lead compound for developing a compound capable of preventing type 2 diabetes mellitus and diseases associated therewith and a method of selecting a therapy to prevent type 2 diabetes mellitus. Also, the invention relates to a kit.

Biomarkers for type 2 diabetes

Growing community of inventors

Dusseldorf, Germany

Christian Herder